Xilio Therapeutics, Inc.XLONASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank36
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P36
Within normal range
vs 2Y Ago
-1.1x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
PeriodValue
Q3 2025-20.85%
Q2 2025-149.96%
Q1 2025304.69%
Q4 2024-3.55%
Q3 2024-168.52%
Q2 2024289.99%
Q1 202421.78%
Q4 2023-0.43%
Q3 202319.34%
Q2 202334.36%
Q1 2023-38.56%
Q4 20228.47%
Q3 2022-18.82%
Q2 202219.58%
Q1 2022-21.40%
Q4 202117.17%
Q3 2021-2.90%
Q2 202111.43%
Q1 2021-78.94%
Q4 2020-21.45%
Q3 2020-130368.94%
Q2 2020-63.40%
Q1 20200.00%